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OBJECTIVES: During the 1990’s, colorectal patients in the U.S.
experienced 6.5 extra hospital days and $3089 in costs attribut-
able to surgical wound infections, but no updated information
is available. We utilized a large U.S. hospital database to iden-
tify the variables associated with increased length of stay (LOS)
and costs for colon procedures. METHODS: We utilized a ret-
rospective comparative national database to assess LOS and
costs in 196 hospitals from 1/1/2005 through June 30, 2006. The
study population was all patients >18 years, identiﬁed via ICD-
9 & CPT procedure codes for elective colon procedures. Patients
given cefotetan as surgical prophylaxis were compared to
patients given commonly used prophylactic antimicrobials,
including cefazolin/metronidazole. Patient demographics, surgi-
cal procedure, primary diagnosis, co-morbidities, and patient
severity were examined as predictors of LOS <7 days and cost
>=$15,000 using logistic regression. Patient severity was classi-
ﬁed by APR-DRG severity of illness subclasses and SENIC risk
index for infection. RESULTS: Hospitals were mostly urban
(90%) with >300 beds (70%), and 58% were non-teaching.
They represented each region of the U.S., though predominantly
Mid- and South-Atlantic (44.0). The 23,801 unique patients
were 51% >65 years, 53% female, and 73% white. The overall
infection rate was 3.3%; mean LOS 7.0 (SD 5.7); mean total cost
$12,871 (SD $11,295); and mean daily cost $2015 (SD $917).
In an adjusted model, compared to cefazolin/metronidazole,
cefotetan is associated with a lower rate of LOS 7 days or more
(OR = 0.92; p = 0.007) and total cost >=$15,000 (OR = 0.71; 
p < 0.001). Additional predictors of greater LOS and costs are
elevated severity (OR = 9.02 & 11.53) and SENIC scores (OR
= 1.51 & 4.12), age <75 (OR = 2.18 & 1.66), and non-white
ethnicity (OR = 1.31 & 1.16). CONCLUSION: Cefotetan 
has limited availability and substitutions are increasingly uti-
lized. Yet in elective colon procedures, cefotetan used as surgical
prophylaxis is associated with lower LOS and costs compared to
cefazolin/metronidazole.
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OBJECTIVES: To estimate severe sepsis (SS) incidence, health
resource use and costs during hospitalization in Brazilian private
health care system, and to verify economic impact of drotreco-
gin-alfa activated (DrotAA) treatment. METHODS: We per-
formed a retrospective data analysis of private health plans’
electronic claims between April 2005 and March 2006. SS were
deﬁned according to 2001 ACP/SCCM criteria. Collected data
were: total length of stay (LOS), length of ICU stay (ICU–LOS),
maximum organ dysfunction number achieved during hospital
stay (MOD), average cost per day, and total cost per patient.
RESULTS: Incidence of SS hospitalization among 5.2 million
health plan beneﬁciaries was 2,12/1000, summing up 11,067
patients/year. Cost/day and total hospital cost increased propor-
tionally to MOD: from R$ 2398.00 (patients with 1MOD) to
R$ 2900.00 (4MOD) and from R$ 43,010.00 to R$ 64,276.00.
ICU-LOS varied from 8 to 10 and total-LOS from 18 to 22 days.
Patients with SS with 1MOD represented >75% of the total
number, while with 4MOD were 2% of total population.
DrotAA were given to 1.3% of total SS patients (148). Fifty-three
percent of DrotAA patients had MOD≥ 2, compared to 19% of
the non-DrotAA patients. Average cost of DrotAA per patient
was R$ 38,809.00. Total hospital cost for the whole group of
patients was R$ 498,079,803.00. Thus, DrotAA cost represented
1.2% of hospital costs related to SS. CONCLUSION: Costs with
SS are substantial, and increase with disease severity. Since there
is minor increase in LOS, an increase in daily medical resources
is expected. Patient number receiving DrotAA, and consequently,
additional cost are small relative to SS baseline cost. Thus, pre-
viously described DrotAA beneﬁt on survival and organ dys-
function may outweigh drug costs.
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OBJECTIVES: To study the cost-effectiveness if LVD were
replaced by ETV in a group of patients with CHB in a public
hospital in Hong Kong. METHODS: From a public hospital per-
spective, a decision analytic model was used to study the cost-
effectiveness of 2 years of treatment of ETV in a hypothetical
cohort of 1000 CHB patients; cirrhosis and hepatocarcinoma
(HCC) events were projected to 10 years. Clinical efﬁcacy data
was obtained from a recently published international random-
ized phase III trial in a group of HBeAg negative CHB patients.
The multivariate-adjusted relative risks for events were estimated
by Cox proportional hazards model from a recent Taiwan epi-
demiology study. Local health care costs including drug cost were
used. Cost of management of the different disease states were
adopted from a recently published local cost of illness study and
QALYs were calculated using the utility values obtained from
another recent local study. Hong Kong governmental population
statistics of life expectancy was used for the estimation.
RESULTS: Using a 5% discount rate for all projections, a 2-year
of ETV treatment would incur an extra drug cost of HKD23.5
million (about USD3 million, 1USD = 7.8HKD); yet about
HKD13.8 million (USD1.7 million) would be avoided in 10 years
time due to reduction in compensated and decompensated cir-
rhosis and HCC. The incremental cost-effectiveness for ETV is
about HKD24,000 (about USD3000) per life year saved and
HKD30,000 (about USD3800) per QALY saved. CONCLU-
SION: Using the US standard of USD50,000 per QALY in decid-
ing whether a therapy is cost-effective, the present study suggests
ETV to be a more cost-effective treatment relative to LVD for
CHB patients in the Hong Kong public sector.
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